美国多发性硬化的经济负担:直接与间接成本估算
该研究采用患病率法估算2019年美国多发性硬化的经济负担,利用三类索赔数据获取直接成本并对946例患者调查收集间接成本。人均年超额医疗成本为65,612美元。
要点
- 2019年美国多发性硬化估计总经济负担为854亿美元。
- 人均年超额医疗成本65,612美元,其中疾病修正治疗35,154美元。
- 人均间接及非医疗成本18,542美元,纳入照护者成本后为22,875美元。
核心结论
- 多发性硬化是昂贵的慢性病,处方药直接成本和间接生产力损失是重要成本驱动因素。
- 研究结果提示美国多发性硬化的负担被低估。
研究设计与样本
- 采用患病率法估算美国多发性硬化的全国经济负担。
- 直接成本来自三类索赔数据:Medicare Current Beneficiary Survey、Medicare Standard Analytical File和Optum去标识化Normative Health Information System。
- 间接成本通过问卷调查收集,纳入946例多发性硬化患者。
- 直接医疗成本反映多发性硬化患者与无多发性硬化匹配对照的总平均年支付金额之差。
- 因多发性硬化过早死亡导致的未来收入损失使用美国疾病控制与预防中心死亡率数据和Medicare索赔数据计算。
主要发现
- 直接成本三大组成部分为零售处方药(54%)、诊所给药药物及给药(12%)和门诊护理(9%)。
- 多发性硬化患者人均年超额医疗成本为65,612美元;疾病修正治疗为每人35,154美元,占该成本最大比例。
- 每例疾病修正治疗使用者的成本因性别-年龄分层而异,范围为57,202至92,719美元。
- 人均间接及非医疗成本为18,542美元,纳入照护者成本后为22,875美元;过早死亡导致的收入损失、假性出勤和缺勤损失是最大的间接成本组成部分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: A recent report estimated that approximately 1 million adults were living with multiple sclerosis (MS) in the United States. Although MS is rarely the direct cause of death, its debilitating effects on normal body functions can result in considerable disruption to daily living and life roles including work, physical independence, mobility, social interaction, and participation in leisure activities. This study estimated the total economic burden of MS in the United States in 2019. METHODS: This study used a prevalence-based approach to estimate the national economic burden of MS. Claims from 3 sources (Medicare Current Beneficiary Survey, Medicare Standard Analytical File, and Optum de-identified Normative Health Information System) were used to obtain direct costs and a survey was developed to collect indirect costs (e.g., labor market productivity losses, costs of paid and unpaid caregivers, home modification) from 946 patients with MS (PwMS). Direct medical costs reflected the difference in the total average annual amount paid for PwMS vs matched controls without MS. Future earnings loss due to premature death attributable to MS was calculated using Centers for Disease Control and Prevention mortality data and Medicare claims data. RESULTS: The estimated total economic burden was $85.4 billion, with a direct medical cost of $63.3 billion and indirect and nonmedical costs of $22.1 billion. Retail prescription medication (54%); clinic-administered drugs, medication, and administration (12%); and outpatient care (9%) were the 3 largest components of the direct costs. The average excess per-person annual medical costs for PwMS was $65,612; at $35,154 per person, disease-modifying therapies (DMTs) accounted for the largest proportion of this cost. The cost per DMT user ranged from $57,202 to $92,719, depending on sex-age strata. The average indirect and nonmedical costs were $18,542 per PwMS and $22,875 per PwMS if caregivers' costs were included. Lost earnings due to premature death, presenteeism, and absenteeism losses were the largest indirect cost components. DISCUSSION: MS is a costly chronic disease, with direct costs of prescription drugs and indirect productivity loss being important cost drivers. Our findings suggested that the burden of MS in the United States has been underestimated.
引用
- Bebo B, Cintina I, LaRocca N, et al. The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs. Neurology. 2022. PMID: 35418457. doi:10.1212/WNL.0000000000200150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。